Boston-based biotechnology company Elektrofi revealed on Wednesday that it has appointed Paul Herbert to the role of senior vice president of Pharmaceutical Development.
The company said Herbert is a highly experienced senior executive with a proven track record of about 30 years in the pharmaceutical industry.
Herbert is a an expert in product development and manufacturing for particle-based products and has led the development of twelve processes to NDA submission.
Before joining Elektrofi, Herbert served as vice president of Process Development & Engineering at Alkermes, where he led teams of up to 100 individuals in all aspects of drug product operations, including sterile process design, regulatory documentation, CDMO/CMO management, and clinical manufacturing.
Elektrofi is focused on improving administration for a range of medicines, such as monoclonal antibodies, therapeutic proteins and other large molecule drugs. The company's breakthrough formulation platform is designed to enable stabilized, highly concentrated formulations for subcutaneous administration.
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Clario acquires imaging provider NeuroRx
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval